See this page online at: http://www.bioscienceworld.ca/AtriumphoverEczema
Sign up for your subscription and keep up-to-date.
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
According to in-vitro trials run by Allegiance Equity Corp. (Toronto, ON), the anti-inflammatory and antibacterial nature of a key component of the company's drug Relieva, may make the drug useful in treating patients with Atopic Dermatitis, a form of eczema.
Allegiance Equity Corp. licensee, Apollo Pharmaceuticals, conducted the preclinical research studies to characterize the pharmacological profile of the drug and to determine the immunoregulatory effects of the said component. The trials found that the Psorberine inhibited the growth of bacteria and the release of the pro-inflammatory cytokines.
The findings are good news to long-term sufferers of the disease, in providing them with a long-term treatment alternative, but without any side effects or limitations. Current treatments are primarily topical creams and ointments, most of which have side effects or safety concerns that preclude long-term use.
A major clinical trial accepted and published in the American Journal of Therapeutics in 2006, has already found Relieva to be effective in the treatment of psoriasis providing effective relief without side effects.
